Evaluation of KO-2806 as Monotherapy and in Combination Therapies for Advanced Colorectal, NSCLC, Pancreatic, and Renal Cell Carcinomas

The primary objective of the study titled "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors" is not explicitly stated. However, the study focuses on evaluating the efficacy and safety of KO-2806 as a monotherapy and in combination therapies for patients with advanced **solid tumors**. The clinical relevance of this study lies in its potential to provide new therapeutic options for patients with challenging malignancies, including **Colorectal Cancer**, **Non-Small Cell Lung Cancer (NSCLC)**, **Pancreatic Ductal Adenocarcinoma**, and **Renal Cell Carcinoma**. These cancers are known for their poor prognosis and limited treatment options, making the exploration of new therapies crucial for improving patient outcomes.

The clinical trial involves a total of **202 participants** diagnosed with various types of cancer, including **Colorectal Cancer**, **Non-Small Cell Lung Cancer (NSCLC)**, **Pancreatic Ductal Adenocarcinoma**, and **Renal Cell Carcinoma**. The study population comprises both male and female subjects, with an age range corresponding to categories 3 and 4, indicating a broad adult demographic. Participants were selected to include a vulnerable population, ensuring a comprehensive representation of the affected demographic. The trial does not specify particular lifestyle considerations such as diet or physical activity. The selection process was designed to encompass a diverse group, reflecting the general health status of individuals with these medical conditions. Key inclusion or exclusion criteria were not provided by the sponsor.

The clinical trial is designed to evaluate the efficacy and safety of **KO-2806** as a monotherapy and in combination therapies for patients with advanced solid tumors, specifically targeting **Colorectal Cancer**, **Non-Small Cell Lung Cancer (NSCLC)**, **Pancreatic Ductal Adenocarcinoma**, and **Renal Cell Carcinoma**. This is a Phase 1 trial, which is characterized by its exploratory nature, focusing on determining the appropriate dosage and assessing the initial safety profile of the investigational treatment. The trial employs a randomized, double-blind, controlled design to ensure unbiased results and to maintain the integrity of the data collected.

The trial is expected to commence recruitment on March 3, 2025, and is projected to conclude by February 11, 2028. Participants will be involved in the study for a duration that aligns with the trial's timeline, subject to their individual response to the treatment and adherence to the study protocol. The sequence of study visits begins with an inclusion (screening) visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful enrollment, participants will undergo a series of follow-up visits at regular intervals to monitor their response to the treatment and to collect necessary data for the study's endpoints. The end-of-study visit marks the conclusion of a participant's involvement, where final assessments are conducted to evaluate the overall impact of the treatment.

Participants may be subject to early termination from the study if they experience adverse effects that compromise their safety, if they fail to comply with the study protocol, or if they choose to withdraw their consent. The trial's methodology is structured to ensure that all data collected is reliable and that participant safety is prioritized throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details on these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be provided. The trial documentation does not include additional relevant information about drug administration or participant compliance monitoring.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on March 3, 2025, with an estimated completion date of February 11, 2028. Although specific efficacy endpoints and methods for measurement are not detailed, Phase 1 trials often utilize a combination of laboratory tests, imaging studies, and clinical assessments to gather data on the investigational product's effects. The analysis of efficacy data will be conducted in accordance with standard clinical trial protocols, ensuring rigorous and objective evaluation of the investigational product's potential therapeutic benefits.